Complement in disease: a defence system turning offensive

Nature Reviews Nephrology

Volumn 12, Issue 7, 2016, Pages 383-401

  Ricklin, Daniel ^a   Reis, Edimara S ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; FIBRINOGEN; INFLAMMASOME; PATTERN RECOGNITION RECEPTOR; PROTHROMBIN; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BLOOD CLOTTING; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; FOREIGN BODY; GLOMERULOPATHY; HEMODIALYSIS; HEREDITY; HOST RESISTANCE; IMMUNOSURVEILLANCE; INFLAMMATORY DISEASE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; DISEASE MODEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; KIDNEY DISEASES; SIGNAL TRANSDUCTION; THROMBOTIC MICROANGIOPATHIES;

EID: 84969862399     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.70     Document Type: Review

References (181)

1. Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797 (2010
2. Ricklin, D., & Lambris, J. D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831-3838 (2013
3. Reis, E. S., et al. Applying complement therapeutics to rare diseases. Clin. Immunol. 161, 225-240 (2015
4. Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. Complement system part I - molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015
5. Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. Complement system part II: role in immunity. Front. Immunol. 6, 257 (2015
6. Mastellos, D. C., Deangelis, R. A., & Lambris, J. D. Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Semin. Immunol. 25, 29-38 (2013
7. Stephan, A. H., Barres, B. A., & Stevens, B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369-389 (2012
8. Kohl, J. The role of complement in danger sensing and transmission. Immunol. Res. 34, 157-176 (2006
9. Scott, D., & Botto, M. The paradoxical roles of C1q and C3 in autoimmunity. Immunobiology http://dx.doi. org/10.1016/j.imbio.2015.05.001 (2015
10. Kolev, M., Le Friec, G., & Kemper, C. Complement - tapping into new sites and effector systems. Nat. Rev. Immunol. 14, 811-820 (2014
11. Harris, C. L., Heurich, M., Rodriguez de Cordoba, S., & Morgan, B. P. The complotype: dictating risk for inflammation and infection. Trends Immunol. 33, 513-521 (2012
12. Diebolder, C. A., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260-1263 (2014
13. Kouser, L., et al. Emerging and novel functions of complement protein C1q. Front. Immunol. 6, 317 (2015
14. Harboe, M., et al. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol. 47, 373-380 (2009
15. Harboe, M., Ulvund, G., Vien, L., Fung, M., & Mollnes, T. E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138, 439-446 (2004
16. Nilsson, B., & Nilsson Ekdahl, K. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 217, 1106-1110 (2012
17. Morgan, B. P. The membrane attack complex as an inflammatory trigger. Immunobiology http://dx.doi. org/10.1016/j.imbio.2015.04.006 (2015
18. Taylor, R. P., & Lindorfer, M. A. The role of complement in mAb-based therapies of cancer. Methods 65, 18-27 (2014
19. Klos, A., Wende, E., Wareham, K. J., & Monk, P. N. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65, 500-543 (2013); erratum 66, 466 (2014
20. Coulthard, L. G., & Woodruff, T. M. Is the complement activation product C3a a proinflammatory molecule? Re evaluating the evidence and the myth. J. Immunol. 194, 3542-3548 (2015
21. Nordahl, E. A., et al. Activation of the complement system generates antibacterial peptides. Proc. Natl Acad. Sci. USA 101, 16879-16884 (2004
22. Ghebrehiwet, B., Hosszu, K. K., Valentino, A., Ji, Y., & Peerschke, E. I. Monocyte expressed macromolecular C1 and C1q receptors as molecular sensors of danger: implications in SLE. Front. Immunol. 5, 278 (2014
23. Helmy, K. Y., et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927 (2006
24. Zeerleder, S. C1 inhibitor: more than a serine protease inhibitor. Semin. Thromb. Hemost 37, 362-374 (2011
25. Matsushita, M., Endo, Y., & Fujita, T. Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication. Arch. Immunol. Ther. Exp. (Warsz) 61, 273-283 (2013
26. Clark, S. J., & Bishop, P. N. Role of factor H and related proteins in regulating complement activation in the macula, and relevance to age-related macular degeneration. J. Clin. Med. 4, 18-31 (2015
27. Reis, E. S., et al. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J. Immunol. 189, 4797-4805 (2012
28. Lesher, A. M., Nilsson, B., & Song, W. C. Properdin in complement activation and tissue injury. Mol. Immunol. 56, 191-198 (2013
29. Kemper, C., Atkinson, J. P., & Hourcade, D. E. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 28, 131-155 (2010
30. Marsh, J. E., Zhou, W., & Sacks, S. H. Local tissue complement synthesis - fine tuning a blunt instrument. Arch. Immunol. Ther. Exp. (Warsz.) 49, S41-S46 (2001
31. Conway, E. M. Reincarnation of ancient links between coagulation and complement. J. Thromb. Haemost. 13, S121-S132 (2015
32. Ritis, K., et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794-4802 (2006
33. Rayes, J., et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 123, 121-125 (2014
34. Speth, C., et al. Complement and platelets: mutual interference in the immune network. Mol. Immunol. 67, 108-118 (2015
35. Hamad, O. A., et al. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thromb. Haemost. 114, 1207-1217 (2015
36. Ali, H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol. Lett. 128, 36-45 (2010
37. Bohlson, S. S., O'Conner, S. D., Hulsebus, H. J., Ho, M. M., & Fraser, D. A. Complement, c1q, and c1q related molecules regulate macrophage polarization. Front. Immunol. 5, 402 (2014
38. Camous, L., et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117, 1340-1349 (2011
39. Wang, H., Wang, C., Zhao, M. H., & Chen, M. Neutrophil extracellular traps can activate alternative complement pathways. Clin. Exp. Immunol. 181, 518-527 (2015
40. Wu, M. C., et al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl Acad. Sci. USA 110, 9439-9444 (2013
41. Hsieh, C. C., et al. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood 121, 1760-1768 (2013
42. Markiewski, M. M., et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225-1235 (2008
43. Son, M., Santiago-Schwarz, F., Al Abed, Y., & Diamond, B. C1q limits dendritic cell differentiation and activation by engaging LAIR 1. Proc. Natl Acad. Sci. USA 109, E3160-E3167 (2012
44. Li, K., et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 217, 65-73 (2012
45. Hawlisch, H., et al. C5a negatively regulates toll-like receptor 4 induced immune responses. Immunity 22, 415-426 (2005
46. Kemper, C., & Kohl, J. Novel roles for complement receptors in T cell regulation and beyond. Mol. Immunol. 56, 181-190 (2013
47. Dunkelberger, J., Zhou, L., Miwa, T., & Song, W. C. C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity. J. Immunol. 188, 4032-4042 (2012
48. Karsten, C. M., et al. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock in mouse. J. Immunol. 194, 1841-1855 (2015
49. Cardone, J., et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 11, 862-871 (2010
50. Le Friec, G., et al. The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat. Immunol. 13, 1213-1221 (2012
51. Ghannam, A., Fauquert, J. L., Thomas, C., Kemper, C., & Drouet, C. Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation. Mol. Immunol. 58, 98-107 (2014
52. Liszewski, M. K., et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39, 1143-1157 (2013
53. Iwasaki, A., & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343-353 (2015
54. Hajishengallis, G., & Lambris, J. D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 31, 154-163 (2010
55. Morgan, B. P., & Gasque, P. Extrahepatic complement biosynthesis: where, when and why? Clin. Exp. Immunol. 107, 1-7 (1997
56. Leemans, J. C., Kors, L., Anders, H. J., & Florquin, S. Pattern recognition receptors and the inflammasome in kidney disease. Nat. Rev. Nephrol. 10, 398-414 (2014
57. Cheung, K. P., Kasimsetty, S. G., & McKay, D. B. Innate immunity in donor procurement. Curr. Opin. Organ Transplant. 18, 154-160 (2013
58. McCullough, J. W., Renner, B., & Thurman, J. M. The role of the complement system in acute kidney injury. Semin. Nephrol. 33, 543-556 (2013
59. Noris, M., & Remuzzi, G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am. J. Kidney Dis. 66, 359-375 (2015
60. Sacks, S. H., & Zhou, W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 12, 431-442 (2012
61. Song, W. C. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 40, 174-182 (2012
62. Bosmann, M., et al. Complement activation product C5a is a selective suppressor of TLR4 induced, but not TLR3 induced, production of IL 27(p28) from macrophages. J. Immunol. 188, 5086-5093 (2012
63. Seow, V., et al. Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a. J. Immunol. 191, 4308-4316 (2013
64. Ling, G. S., et al. Integrin CD11b positively regulates TLR4 induced signalling pathways in dendritic cells but not in macrophages. Nat. Commun. 5, 3039 (2014
65. Zou, L., et al. Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J. Immunol. 191, 5625-5635 (2013
66. Triantafilou, M., Hughes, T. R., Morgan, B. P., & Triantafilou, K. Complementing the inflammasome. Immunology 147, 152-164 (2016
67. Asgari, E., et al. C3a modulates IL 1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122, 3473-3481 (2013
68. Laudisi, F., et al. Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL 1β release. J. Immunol. 191, 1006-1010 (2013
69. Triantafilou, K., Hughes, T. R., Triantafilou, M., & Morgan, B. P. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 126, 2903-2913 (2013
70. Samstad, E. O., et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 192, 2837-2845 (2014
71. Benoit, M. E., Clarke, E. V., Morgado, P., Fraser, D. A., & Tenner, A. J. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J. Immunol. 188, 5682-5693 (2012
72. Pinto, M. R., Melillo, D., Giacomelli, S., Sfyroera, G., & Lambris, J. D. Ancient origin of the complement system: emerging invertebrate models. Adv. Exp. Med. Biol. 598, 372-388 (2007
73. Flajnik, M. F. Re evaluation of the immunological Big Bang. Curr. Biol. 24, R1060-R1065 (2014
74. Sunyer, J. O., et al. Evolution of complement as an effector system in innate and adaptive immunity. Immunol. Res. 27, 549-564 (2003
75. Carroll, M. C., & Isenman, D. E. Regulation of humoral immunity by complement. Immunity 37, 199-207 (2012
76. Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C., & Fearon, D. T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350 (1996
77. Humphrey, J. H., Grennan, D., & Sundaram, V. The origin of follicular dendritic cells in the mouse and the mechanism of trapping of immune complexes on them. Eur. J. Immunol. 14, 859-864 (1984
78. Karsten, C. M., & Kohl, J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217, 1067-1079 (2012
79. Huang, Z. Y., et al. Interaction of two phagocytic host defense systems: Fcγ receptors and complement receptor 3. J. Biol. Chem. 286, 160-168 (2011
80. Karsten, C. M., et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin 1. Nat. Med. 18, 1401-1406 (2012
81. Bosmann, M., & Ward, P. A. The inflammatory response in sepsis. Trends Immunol. 34, 129-136 (2013
82. Ward, P. A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4, 133-142 (2004
83. Silasi-Mansat, R., et al. Complement inhibition decreases early fibrogenic events in the lung of septic baboons. J. Cell. Mol. Med. 19, 2549-2563 (2015
84. Silasi-Mansat, R., et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116, 1002-1010 (2010
85. Barratt-Due, A., et al. Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. J. Immunol. 191, 819-827 (2013
86. Egge, K. H., et al. The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin. Exp. Immunol. 181, 457-467 (2015
87. Burk, A. M., et al. Early complementopathy after multiple injuries in humans. Shock 37, 348-354 (2012
88. Ganter, M. T., et al. Role of the alternative pathway in the early complement activation following major trauma. Shock 28, 29-34 (2007
89. Huber-Lang, M., Kovtun, A., & Ignatius, A. The role of complement in trauma and fracture healing. Semin. Immunol. 25, 73-78 (2013
90. Rafail, S., et al. Complement deficiency promotes cutaneous wound healing in mice. J. Immunol. 194, 1285-1291 (2015
91. Brennan, F. H., et al. The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. J. Neurosci. 35, 6517-6531 (2015
92. Chen, M., Daha, M. R., & Kallenberg, C. G. The complement system in systemic autoimmune disease. J. Autoimmun. 34, J276-286 (2010
93. Chen, M., & Kallenberg, C. G. ANCA-associated vasculitides - advances in pathogenesis and treatment. Nat. Rev. Rheumatol. 6, 653-664 (2010
94. Banz, Y., & Rieben, R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann. Med. 44, 205-217 (2012
95. Zipfel, P. F., et al. The role of complement in C3 glomerulopathy. Mol. Immunol. 67, 21-30 (2015
96. Orsini, F., De Blasio, D., Zangari, R., Zanier, E. R., & De Simoni, M. G. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front. Cell. Neurosci. 8, 380 (2014
97. Veerhuis, R., Nielsen, H. M., & Tenner, A. J. Complement in the brain. Mol. Immunol. 48, 1592-1603 (2011
98. Hovland, A., et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis 241, 480-494 (2015
99. Morgan, B. P. The role of complement in neurological and neuropsychiatric diseases. Expert Rev. Clin. Immunol. 11, 1109-1119 (2015
100. Patzelt, J., Verschoor, A., & Langer, H. F. Platelets and the complement cascade in atherosclerosis. Front. Physiol. 6, 49 (2015
101. McHarg, S., Clark, S. J., Day, A. J., & Bishop, P. N. Age-related macular degeneration and the role of the complement system. Mol. Immunol. 67, 43-50 (2015
102. Ekdahl, K. N., et al. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 63, 1042-1050 (2011
103. Grumach, A. S., & Kirschfink, M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 61, 110-117 (2014
104. Risitano, A. M. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217, 1080-1087 (2012
105. Rodriguez, E., Rallapalli, P. M., Osborne, A. J., & Perkins, S. J. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci. Rep. 34, 5 (2014
106. Hageman, G. S., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA 102, 7227-7232 (2005
107. Weismann, D., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478, 76-81 (2011
108. Heurich, M., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc. Natl Acad. Sci. USA 108, 8761-8766 (2011
109. Kurts, C., Panzer, U., Anders, H. J., & Rees, A. J. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738-753 (2013
110. Song, D., Zhou, W., Sheerin, S. H., & Sacks, S. H. Compartmental localization of complement component transcripts in the normal human kidney. Nephron 78, 15-22 (1998
111. Noris, M., & Remuzzi, G. Overview of complement activation and regulation. Semin. Nephrol. 33, 479-492 (2013
112. Clark, S. J., et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J. Immunol. 190, 2049-2057 (2013
113. Jozsi, M., Tortajada, A., Uzonyi, B., Goicoechea de Jorge, E., & Rodriguez de Cordoba, S. Factor H related proteins determine complement-activating surfaces. Trends Immunol. 36, 374-384 (2015
114. Noris, M., Mescia, F., & Remuzzi, G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8, 622-633 (2012
115. Kenawy, H. I., Boral, I., & Bevington, A. Complement-coagulation cross-talk: a potential mediator of the physiological activation of complement by low pH. Front. Immunol. 6, 215 (2015
116. George, J. N., & Nester, C. M. Syndromes of thrombotic microangiopathy. N. Engl. J. Med. 371, 654-666 (2014
117. Riedl, M., et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin. Thromb. Hemost 40, 444-464 (2014
118. Mele, C., Remuzzi, G., & Noris, M. Hemolytic uremic syndrome. Semin. Immunopathol. 36, 399-420 (2014
119. Noris, M., et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124, 1715-1726 (2014
120. Frimat, M., et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122, 282-292 (2013
121. Zuber, J., et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8, 643-657 (2012
122. Cofiell, R., et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125, 3253-3262 (2015
123. Morgan, B. P., & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14, 857-877 (2015
124. Meri, S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur. J. Intern. Med. 24, 496-502 (2013
125. Morigi, M., et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187, 172-180 (2011
126. Nester, C. M., & Brophy, P. D. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr. Opin. Pediatr. 25, 225-231 (2013
127. Pecoraro, C., et al. Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab. Am. J. Kidney Dis. 66, 1067-1070 (2015
128. Phillips, E. H., et al. The role of ADAMTS 13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J. Thromb. Haemost. 14, 175-185 (2016
129. Tsai, E., Chapin, J., Laurence, J. C., & Tsai, H. M. Use of eculizumab in the treatment of a case of refractory, ADAMTS13 deficient thrombotic thrombocytopenic purpura: additional data and clinical follow up. Br. J. Haematol. 162, 558-559 (2013
130. Pickering, M. C., et al. C3 glomerulopathy: consensus report. Kidney Int. 84, 1079-1089 (2013
131. Cook, H. T., & Pickering, M. C. Histopathology of MPGN and C3 glomerulopathies. Nat. Rev. Nephrol. 11, 14-22 (2015
132. Servais, A., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454-464 (2012
133. Martinez-Barricarte, R., et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120, 3702-3712 (2010
134. Xiao, X., Pickering, M. C., & Smith, R. J. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin. Thromb. Hemost. 40, 465-471 (2014
135. Damman, J., et al. Hypoxia and complement-and-coagulation pathways in the deceased organ donor as the major target for intervention to improve renal allograft outcome. Transplantation 99, 1293-1300 (2015
136. Amura, C. R., et al. Complement activation and toll-like receptor 2 signaling contribute to cytokine production after renal ischemia/reperfusion. Mol. Immunol. 52, 249-257 (2012
137. Farrar, C. A., et al. Collectin 11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. J. Clin. Invest. 126, 1911-19 (2016
138. Muller, T. F., Kraus, M., Neumann, C., & Lange, H. Detection of renal allograft rejection by complement components C5A and TCC in plasma and urine. J. Lab. Clin. Med. 129, 62-71 (1997
139. Stites, E., Le Quintrec, M., & Thurman, J. M. The complement system and antibody-mediated transplant rejection. J. Immunol. 195, 5525-5531 (2015
140. Pratt, J. R., Basheer, S. A., & Sacks, S. H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat. Med. 8, 582-587 (2002
141. Strainic, M. G., Shevach, E. M., An, F., Lin, F., & Medof, M. E. Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF β1 signaling and induction of Foxp3+ regulatory T cells. Nat. Immunol. 14, 162-171 (2013
142. Van Der Touw, W., et al. Cutting edge: receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J. Immunol. 190, 5921-5925 (2013
143. Marsh, J. E., et al. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation 72, 1310-1318 (2001
144. Thomas, K. A., Valenzuela, N. M., & Reed, E. F. The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol. Med. 21, 319-329 (2015
145. Chen Song, S., et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 11, 2057-2066 (2011
146. Fremeaux-Bacchi, V., & Legendre, C. M. The emerging role of complement inhibitors in transplantation. Kidney Int. 88, 967-973 (2015
147. DeAngelis, R. A., Reis, E. S., Ricklin, D., & Lambris, J. D. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 217, 1097-1105 (2012
148. Kourtzelis, I., et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116, 631-639 (2010
149. Ricklin, D., & Lambris, J. D. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190, 3839-3847 (2013
150. Licht, C., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2 year extensions of phase 2 studies. Kidney Int. 87, 1061-1073 (2015
151. Wong, E. K., & Kavanagh, D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl. Res. 165, 306-320 (2015
152. Eskandary, F., Wahrmann, M., Muhlbacher, J., & Bohmig, G. A. Complement inhibition as potential new therapy for antibody-mediated rejection. Transpl. Int. 29, 392-402 (2016
153. Stegall, M. D., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11, 2405-2413 (2011
154. Cornell, L. D., Schinstock, C. A., Gandhi, M. J., Kremers, W. K., & Stegall, M. D. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am. J. Transplant. 15, 1293-2302 (2015
155. Ricklin, D., & Lambris, J. D. Therapeutic control of complement activation at the level of the central component C3. Immunobiology http://dx.doi. org/10.1016/j.imbio.2015.06.012 (2015
156. Zhang, Y., et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J. Am. Soc. Nephrol. 24, 1820-1829 (2013
157. Sacks, S., et al. Targeting complement at the time of transplantation. Adv. Exp. Med. Biol. 735, 247-255 (2013
158. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02247531 (2016
159. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02247479 (2016
160. Zhang, Y., et al. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 220, 993-998 (2015
161. Risitano, A. M., et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123, 2094-2101 (2014
162. Reis, E. S., et al. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 220, 476-482 (2015
163. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02264639 (2016
164. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02503332 (2016
165. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02588833 (2016
166. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02502903 (2015
167. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02222545 (2015
168. Vo, A. A., et al. A phase I/II placebo-controlled trial of C1 inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99, 299-308 (2015
169. ChemoCentryx. ChemoCentryx announces positive results in phase II ANCA-associated vasculitis CLEAR trial of orally administered complement 5a receptor inhibitor CCX168. http://ir.chemocentryx.com/releasedetail.cfm?releaseid=948998 (2016
170. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02384317 (2016
171. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02464891 (2015
172. US National Library of Science. Clinical Trials.gov https://Clinical Trials.gov/show/NCT02246595 (2016
173. Hillmen, P., et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 162, 62-73 (2013
174. Wu, M. A., Zanichelli, A., Mansi, M., & Cicardi, M. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin. Pharmacother. 17, 27-40 (2016
175. Banda, N. K., et al. Mechanisms of mannose-binding lectin-associated serine proteases 1/3 activation of the alternative pathway of complement. Mol. Immunol. 49, 281-289 (2011
176. Dobo, J., et al. Multiple roles of complement MASP 1 at the interface of innate immune response and coagulation. Mol. Immunol. 61, 69-78 (2014
177. Arnold, J. N., Royle, L., Dwek, R. A., Rudd, P. M., & Sim, R. B. Human immunoglobulin glycosylation and the lectin pathway of complement activation. Adv. Exp. Med. Biol. 564, 27-43 (2005
178. Amara, U., et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185, 5628-5636 (2010
179. Inforzato, A., et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin. Immunol. 25, 79-85 (2013
180. Csincsi, A. I., et al. Factor H related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J. Immunol. 194, 4963-4973 (2015
181. Trouw, L. A., Blom, A. M., & Gasque, P. Role of complement and complement regulators in the removal of apoptotic cells. Mol. Immunol. 45, 1199-1207 (2008